UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55
UBS analyst Ashwani Verma initiates coverage on Crinetics Pharmaceuticals (NASDAQ: CRNX ) with a Buy rating and announces Price Target of $55.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.